GB2638094B - IL-21 Polypeptides And Targeted Constructs - Google Patents
IL-21 Polypeptides And Targeted ConstructsInfo
- Publication number
- GB2638094B GB2638094B GB2503987.6A GB202503987A GB2638094B GB 2638094 B GB2638094 B GB 2638094B GB 202503987 A GB202503987 A GB 202503987A GB 2638094 B GB2638094 B GB 2638094B
- Authority
- GB
- United Kingdom
- Prior art keywords
- polypeptides
- targeted constructs
- constructs
- targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190669P | 2021-05-19 | 2021-05-19 | |
| US202163223684P | 2021-07-20 | 2021-07-20 | |
| PCT/US2021/056312 WO2022087458A1 (en) | 2020-10-23 | 2021-10-22 | Fusions with cd8 antigen binding molecules for modulating immune cell function |
| PCT/US2021/062485 WO2022125712A1 (en) | 2020-12-09 | 2021-12-08 | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function |
| US202263297631P | 2022-01-07 | 2022-01-07 | |
| GB2319093.7A GB2623654C (en) | 2021-05-19 | 2022-04-27 | IL-21 polypeptides and targeted constructs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB202503987D0 GB202503987D0 (en) | 2025-04-30 |
| GB2638094A GB2638094A (en) | 2025-08-13 |
| GB2638094B true GB2638094B (en) | 2026-03-04 |
Family
ID=84141859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2503987.6A Active GB2638094B (en) | 2021-05-19 | 2022-04-27 | IL-21 Polypeptides And Targeted Constructs |
| GB2319093.7A Active GB2623654C (en) | 2021-05-19 | 2022-04-27 | IL-21 polypeptides and targeted constructs |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2319093.7A Active GB2623654C (en) | 2021-05-19 | 2022-04-27 | IL-21 polypeptides and targeted constructs |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US12122827B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4340866A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7873681B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240024829A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022275666A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3219181A1 (cg-RX-API-DMAC7.html) |
| GB (2) | GB2638094B (cg-RX-API-DMAC7.html) |
| IL (1) | IL308609A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023013723A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202306988A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022245500A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022245500A1 (en) | 2021-05-19 | 2022-11-24 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| CN119546343A (zh) * | 2022-04-27 | 2025-02-28 | 亚设生物治疗公司 | 细胞因子融合蛋白与cd8抗原结合分子的组合 |
| WO2025191133A1 (en) * | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
| WO2025191139A1 (en) * | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Conjugates of her2-specific antigen binding proteins and cytokines |
| WO2025229623A1 (en) * | 2024-05-03 | 2025-11-06 | Peptone, Ltd. | Engineered cytokines and uses thereof |
| CN119954930B (zh) * | 2025-02-12 | 2025-12-02 | 华润生物医药有限公司 | Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6940003B1 (en) | 1998-12-03 | 2005-09-06 | E. I. Du Pont De Nemours And Company | Plan lecithin: cholesterol acyltransferases |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| EP2130919A1 (en) | 2001-11-05 | 2009-12-09 | ZymoGenetics, Inc. | IL-21 antagonists |
| US7276478B2 (en) | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| AU2006237329B2 (en) | 2005-04-18 | 2012-04-12 | Novo Nordisk A/S | IL-21 variants |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| EP2109620B1 (en) | 2006-12-21 | 2012-08-22 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
| EP3127921A1 (en) * | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| WO2009149382A2 (en) | 2008-06-06 | 2009-12-10 | Baylor Research Institute | Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells |
| US20120107267A1 (en) | 2009-03-11 | 2012-05-03 | Novo Nordisk A/S | Interleukin-21 variants having antagonistic binding to the il-21 receptor |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| RU2013139267A (ru) | 2011-02-10 | 2015-03-20 | Рош Гликарт Аг | Улучшенная иммунотерапия |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| US20150191543A1 (en) | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| PL3434695T3 (pl) | 2012-08-07 | 2021-05-17 | Roche Glycart Ag | Ulepszona immunoterapia |
| WO2014023709A1 (en) | 2012-08-09 | 2014-02-13 | Roche Glycart Ag | Asgpr antibodies and uses thereof |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| PT3102595T (pt) | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| DK3189081T3 (da) | 2014-09-05 | 2020-05-04 | Janssen Pharmaceutica Nv | Cd123-bindende midler og anvendelser deraf |
| WO2016100375A2 (en) | 2014-12-15 | 2016-06-23 | Washington University | Compositions and methods for targeted cytokine delivery |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| AU2016312259B2 (en) | 2015-08-26 | 2018-12-06 | Bison Therapeutics Inc. | Multispecific antibody platform and related methods |
| JP7014724B2 (ja) | 2016-02-06 | 2022-02-01 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Fab免疫グロブリンおよびその使用 |
| AR108034A1 (es) | 2016-02-17 | 2018-07-11 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
| WO2018106972A1 (en) | 2016-12-07 | 2018-06-14 | La Jolla Institute For Allergy And Immunology | Compositions for cancer treatment and methods and uses for cancer treatment and prognosis |
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| WO2018170096A1 (en) | 2017-03-14 | 2018-09-20 | Dualogics, Llc | Use of a cd4/cd8 bispecific antibody for the treatment of diabetes |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| CN107082812B (zh) | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
| WO2018209115A1 (en) | 2017-05-10 | 2018-11-15 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| AU2018287317B2 (en) | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| US20200306301A1 (en) | 2017-07-03 | 2020-10-01 | Torque Therapeutics, Inc. | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof |
| CN110997013B (zh) | 2017-07-24 | 2022-09-20 | 瑞泽恩制药公司 | 抗cd8抗体和其用途 |
| SG11202000820PA (en) | 2017-07-31 | 2020-02-27 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| CN118126157A (zh) | 2017-08-03 | 2024-06-04 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
| EP3665201A4 (en) | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| WO2019033043A2 (en) | 2017-08-11 | 2019-02-14 | Genentech, Inc. | ANTI-CD8 ANTIBODIES AND USES THEREOF |
| SG11202000387YA (en) | 2017-08-25 | 2020-03-30 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
| JP2020533971A (ja) | 2017-08-28 | 2020-11-26 | アルター・バイオサイエンス・コーポレーション | Il−15をベースとするil−7及びil−21への融合物 |
| KR102777151B1 (ko) | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| US11970537B2 (en) | 2017-12-26 | 2024-04-30 | Nanjing GenScript Biotech Co., Ltd. | Fusion protein dimer using antibody Fc region as backbone and use thereof |
| MX2020007291A (es) * | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
| MX387358B (es) | 2018-02-28 | 2025-03-18 | Pfizer | Variantes de il-15 y usos de las mismas |
| KR20260100427A (ko) | 2018-03-28 | 2026-06-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 이작용성 단백질 및 이의 작제물 |
| CA3095498A1 (en) | 2018-04-09 | 2019-10-17 | Origincell Therapeutics Co., Ltd. | Anti-pd-l1 antibody and use thereof |
| AU2019288496B2 (en) | 2018-06-22 | 2024-11-21 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
| MX2020014290A (es) | 2018-06-22 | 2021-08-05 | Cugene Inc | Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos. |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| GB201900732D0 (en) | 2019-01-18 | 2019-03-06 | Ucb Biopharma Sprl | Antibodies |
| JP7778571B2 (ja) | 2019-06-05 | 2025-12-02 | アッシャー バイオセラピューティクス, インコーポレイテッド | 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体 |
| JP2022538139A (ja) | 2019-07-02 | 2022-08-31 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 変異体インターロイキン-2及び抗cd8抗体を含む免疫複合体 |
| EP4175979A2 (en) | 2020-07-02 | 2023-05-10 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| KR20230086765A (ko) | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| JP2023553216A (ja) | 2020-12-09 | 2023-12-20 | アシャ バイオセラピューティクス,インク. | 遺伝子操作細胞療法のための標的化サイトカイン構築物 |
| AU2021396247A1 (en) | 2020-12-09 | 2023-07-06 | Asher Biotherapeutics, Inc. | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function |
| WO2022135469A1 (zh) | 2020-12-23 | 2022-06-30 | 信达生物制药(苏州)有限公司 | 白细胞介素21突变体以及其用途 |
| WO2022245500A1 (en) | 2021-05-19 | 2022-11-24 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| KR20230044130A (ko) | 2021-09-24 | 2023-04-03 | 바이오엔시스템스 주식회사 | Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도 |
| WO2023052846A2 (en) | 2021-09-30 | 2023-04-06 | Ildong Pharmaceutical Co., Ltd. | Immunocytokine containing il-21r mutein |
-
2022
- 2022-04-27 WO PCT/US2022/026584 patent/WO2022245500A1/en not_active Ceased
- 2022-04-27 IL IL308609A patent/IL308609A/en unknown
- 2022-04-27 EP EP22805153.8A patent/EP4340866A4/en active Pending
- 2022-04-27 MX MX2023013723A patent/MX2023013723A/es unknown
- 2022-04-27 CA CA3219181A patent/CA3219181A1/en active Pending
- 2022-04-27 AU AU2022275666A patent/AU2022275666A1/en active Pending
- 2022-04-27 GB GB2503987.6A patent/GB2638094B/en active Active
- 2022-04-27 JP JP2023571500A patent/JP7873681B2/ja active Active
- 2022-04-27 KR KR1020237043732A patent/KR20240024829A/ko active Pending
- 2022-04-27 GB GB2319093.7A patent/GB2623654C/en active Active
- 2022-04-28 TW TW111116220A patent/TW202306988A/zh unknown
-
2023
- 2023-04-26 US US18/307,477 patent/US12122827B2/en active Active
- 2023-04-27 US US18/308,338 patent/US12247072B2/en active Active
-
2024
- 2024-10-14 US US18/915,009 patent/US20250034242A1/en active Pending
-
2025
- 2025-03-05 US US19/071,326 patent/US20250197489A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2623654A8 (en) | 2024-09-18 |
| JP7873681B2 (ja) | 2026-06-12 |
| GB202503987D0 (en) | 2025-04-30 |
| US20230357343A1 (en) | 2023-11-09 |
| US12122827B2 (en) | 2024-10-22 |
| TW202306988A (zh) | 2023-02-16 |
| EP4340866A4 (en) | 2025-05-21 |
| KR20240024829A (ko) | 2024-02-26 |
| GB2623654C (en) | 2025-09-24 |
| US20250034242A1 (en) | 2025-01-30 |
| US12247072B2 (en) | 2025-03-11 |
| IL308609A (en) | 2024-01-01 |
| GB202319093D0 (en) | 2024-01-31 |
| GB2638094A (en) | 2025-08-13 |
| US20230340104A1 (en) | 2023-10-26 |
| CA3219181A1 (en) | 2022-11-24 |
| GB2623654A (en) | 2024-04-24 |
| AU2022275666A1 (en) | 2023-12-07 |
| GB2623654B (en) | 2025-08-06 |
| EP4340866A1 (en) | 2024-03-27 |
| US20250197489A1 (en) | 2025-06-19 |
| JP2024522069A (ja) | 2024-06-11 |
| WO2022245500A1 (en) | 2022-11-24 |
| MX2023013723A (es) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2623654C (en) | IL-21 polypeptides and targeted constructs | |
| IL317516A (en) | RNA structures and their uses | |
| IL277542A (en) | CD22-targeting constructs and uses thereof | |
| IL300121A (en) | Anti-cd93 constructs and uses thereof | |
| ZA202006905B (en) | Gene therapy constructs and methods of use | |
| IL285285A (en) | Pairs of il-2 and their uses | |
| GB202001196D0 (en) | Activatable protein constructs and uses thereof | |
| SG11202100208VA (en) | Fusion constructs and methods of using thereof | |
| IL268346A (en) | Targeted chimeric proteins and their uses | |
| IL290279A (en) | Implantable structures and their use | |
| SG11202009697RA (en) | Micro rna expression constructs and uses thereof | |
| EP3833391A4 (en) | ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF | |
| IL292259A (en) | flt3-targeted antibodies and their uses | |
| IL312573A (en) | Mobile elements and their chimeric structures | |
| IL319851A (en) | LRRC-15 binding protein structures and uses thereof | |
| IL270024A (en) | Lamp and solar structures in the vaccine | |
| IL304118A (en) | Phrase structures and their uses | |
| IL282987A (en) | Delivery constructs for transcytosis and related methods | |
| SG11202111462VA (en) | Asx-specific protein ligases and uses thereof | |
| IL288685A (en) | Antigen-binding protein structures and uses thereof | |
| PT3989962T (pt) | Terapia de combinação com acetil-leucina e miglustato para tratamento de uma doença de armazenamento lisossómico | |
| IL311972A (en) | Activatable Cytokine Structures and Conjugation Methods | |
| IL286799A (en) | Consolidated structures and their uses | |
| GB202013709D0 (en) | Aquafaba products and methods | |
| IL319652A (en) | RNA structures and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40129535 Country of ref document: HK |